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EDITORIAL SUMMARY:  Here the Authors provide an extension to their earlier RNA 10 
interactome capture protocol, describing RBDmap; a method to identify the regions 11 
of RNA-binding proteins (RBPs) engaged in native interactions with RNA, in a 12 
proteome-wide manner. 13 
TWEET: RBDmap - an extension of the RNA Interactome Capture method to identify 14 





RBDmap identifies, in a proteome-wide manner, the regions of RNA-binding proteins 20 
(RBPs) engaged in native interactions with RNA. In brief, cells are irradiated with UV 21 
light to induce protein-RNA crosslinks. Resulting covalently linked protein-RNA 22 
complexes are purified with oligo(dT) magnetic beads, following stringent denaturing 23 
washes. After elution, RBPs are subjected to partial proteolysis, where the protein 24 
regions still bound to the RNA and those released to the supernatant are separated 25 
by a second oligo(dT) selection. After sample preparation and mass spectrometric 26 
analysis, peptide intensity ratios between the RNA-bound and released fractions are 27 
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used to determine the RNA-binding regions. As a Protocol Extension, this article 1 
describes an adaptation of an existing Protocol, and offers additional applications. The 2 
earlier protocol (for the RNA interactome Capture method) describes how to identify 3 
the active RBPs of cultured cells, whilst this Protocol Extension enables the 4 
identification of the RNA-binding domains of RBPs in cultured cells. The experimental 5 
workflow takes one week, plus two additional weeks for proteomics and data analysis. 6 
Notably, RBDmap presents numerous advantages over classical methods to 7 
determine RNA-binding domains: it produces proteome-wide, high resolution maps of 8 
the protein regions contacting the RNA in a physiological context and can be adapted 9 
to different biological systems and conditions. Because RBDmap relies on the isolation 10 
of polyadenylated RNA via oligo(dT), it will not provide RNA-binding information on 11 
proteins interacting exclusively with non-polyadenylated transcripts. Applied to HeLa 12 
cells, RBDmap uncovered 1,174 RNA-binding sites in 529 proteins, many of which 13 
were previously unknown.  14 
 15 
INTRODUCTION 16 
RNA is a key molecule in cell biology that displays a broad variety of functions, 17 
including not only its well-studied role as a template of protein synthesis (mRNA) but 18 
also its activity as structural component of cellular machines (e.g. rRNA), regulator of 19 
gene expression (e.g. miRNA and non-coding RNA) and catalytic core (e.g. 20 
ribozymes). RNA-binding proteins (RBPs) associate with RNA from synthesis to decay 21 
forming dynamic ribonucleoproteins (RNPs) that regulate RNA fate. In spite of the 22 
relevance of RBPs in the RNA’s life, the diversity of cellular proteins enabled with 23 
RNA-binding activity remained largely unknown. The most well-characterized RBPs, 24 
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referred to here as ‘classical’, are distinguished by the presence of one or multiple 1 
well-known RNA-binding domains (RBDs), such as the RNA recognition motif (RRM), 2 
the K-homology domain (KH), cold shock domain (CSD), the DEAD box helicase 3 
domain, the double stranded RNA-binding domain (dsRBD) and others (see complete 4 
list in1). Interestingly, the architecture of classical RBPs often follows a modular design 5 
combining multiple, typically globular, RBDs within the same protein to increase RNA-6 
binding selectivity and affinity1,2.  7 
In the last three decades, numerous RBPs lacking classical RBDs were discovered in 8 
a stepwise fashion, raising the possibility of unexplored modes of RNA-binding3-7. 9 
Recent work from our laboratory and others combined in vivo ultraviolet (UV) 10 
crosslinking, stringent oligo(dT) isolation of polyadenylated RNA and quantitative 11 
mass spectrometry to determine the repertoire of cellular RBPs8,9. This method, called 12 
RNA interactome capture10, added hundreds of non-canonical RBPs to the previously 13 
known repertoire of RBPs, including metabolic enzymes, protein chaperons, and 14 
cytoskeleton-associated proteins8,9. RNA interactome capture has recently been 15 
applied to other cell lines and organisms, including Saccharomyces cerevisiae, 16 
Plasmodium falciparum, Caenorhabditis elegans, Drosophila melanogaster and 17 
plants, providing unprecedented insights into the diversity of RBPs and their evolution 18 
across species11-23. RNA interactome capture has also been combined with 19 
subcellular fractionation, implementing a DNase step to reduce the incidence of DNA 20 
in the nuclear preparation21.  Many of the RBPs discovered by these studies have 21 
been shown to play important roles in RNA biology13,24-27 and many others are 22 
currently under investigation. However, it remained largely unknown how these novel 23 
RBPs interact with RNA.  24 
5 
 
Classical methods to identify RBDs effectively determined the regions involved in RNA 1 
binding using individual proteins and deletion or substitution mutagenesis (e.g.28). 2 
However, these methods are unsuitable for proteome-wide RBD discovery, calling for 3 
different experimental approaches. Here we describe RBDmap, an extension of the 4 
RNA interactome method10, that combines UV crosslinking, oligo(dT) capture, 5 
controlled proteolysis and mass spectrometry to discover high-confidence RNA-6 
binding sites on a proteome-wide scale (Figure 1). Applied to HeLa cells, RBDmap 7 
identified 1174 binding sites within 529 human RBPs, including both classical and 8 
unorthodox RBPs29. RBDmap has also proven its utility in HL-1 cardiomyocytes, where 9 
RBDmap dissected the RNA-binding regions of 368 murine proteins30.  10 
 11 
Overview of the protocol 12 
RBDmap (Figure 1) employs two alternative UV crosslinking approaches to immobilize 13 
native protein-RNA interactions in cultured cells. The first approach, referred to as 14 
conventional UV crosslinking (cCL), exploits the intrinsic reactivity of nucleotide bases 15 
to irradiation with UV light at 254 nm. At this wavelength, UV irradiation induces short-16 
lived, free radicals at the nucleotide bases that attack amino acids at “zero” distance 17 
to form covalent bonds31. In parallel, we used photoactivatable ribonucleoside–18 
enhanced crosslinking (PAR-CL) that employs 4-thiouridine (4SU). This nucleotide 19 
analogue is taken up by cultured cells and incorporated into nascent RNAs. 20 
Crosslinking is achieved after irradiation with 365 nm UV light8,9. Since the absorbance 21 
of natural bases at this wavelength is negligible, protein-RNA crosslinks are 4SU-22 
dependent. Since RBPs can differ in their crosslinking efficiencies with either of the 23 
two protocols9, we applied both cCL and PAR-CL in parallel to enhance RBD 24 
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identification. After denaturing cell lysis, polyadenylated RNA and its covalently bound 1 
proteins are purified under stringent washing conditions by hybridization with oligo(dT) 2 
coupled to magnetic beads. After elution at 55°C, RBP-RNA complexes are treated 3 
with a protease (LysC or ArgC) that cleaves every 17 amino acids on average. 4 
Proteolytic treatment generates two types of RBP fragments: i) peptides that remain 5 
crosslinked to the RNA and include the RNA-binding site; and ii) peptides that are 6 
released into the supernatant which correspond to protein regions that are not bound 7 
(or crosslinked) to RNA, referred to as “released peptides” (Figure 1). Both classes of 8 
protein fragments are separated by a second oligo(dT) isolation, where the 9 
supernatant contains the released protein fragments and the bead-retained fraction is 10 
enriched for RNA-bound fragments (Figure 1). Both the supernatant and the elution of 11 
the second oligo(dT) capture are treated with RNases and trypsin, and subsequently 12 
analyzed by mass spectrometry (MS). Because trypsin cleaves every 8 amino acids 13 
(aa) on average, the ~17 aa RNA-bound protein fragments will be cleaved into a 14 
peptide(s) that remains covalently linked to one or more nucleotides (X-link peptide) 15 
and its neighboring tryptic peptides (N-link) that are released (Figure 1). While the X-16 
link peptide cannot be readily identified due to the nucleotide remnant32,33, the N-link 17 
peptide(s) can be identified by conventional MS. RNA-binding sites are determined by 18 
comparing the ratio of each N-link peptide in the RNA-bound versus the released 19 
fraction, applying a 1% false discovery rate (FDR) as the statistical cut off (Figure 2A). 20 
Peptides classified as “RNA-binding” correspond to the MS-identifiable N-link moiety, 21 
and their boundaries are extended in silico to the nearest LysC or ArgC cleavage sites 22 
to recapitulate the original fragment generated by these proteases, which contains the 23 
actual RNA-binding site. These fragments with an average length of 17 aa are referred 24 
to as “RBDpeps”.       25 
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Advantages of the method in comparison to other approaches 1 
RBDs are classically mapped by loss-of-function approaches, which involve the 2 
generation of single point or deletion mutants that are tested for RNA binding in vitro 3 
by EMSA assays28 or in vivo by crosslinking and immunoprecipitation (CLIP) followed 4 
by T4 polynucleotide kinase (PNK) assay or fluorescence-based methods11,34. In 5 
contrast to CLIP followed by PNK labeling and classical EMSA assays, RBDmap does 6 
not require the use of radioactivity. While commonly successful, the limited number of 7 
mutations that can be generated and tested often impacts on the resolution of the RBD 8 
mapping, especially when the boundaries of the structural fold associated with RNA 9 
binding are not well defined. Mutations can cause protein misfolding, mislocalisation 10 
or dysfunction, limiting the utility of this approach. Furthermore, the work required for 11 
cloning, expression and purification limit this approach to a small number of cases at 12 
a time. RBDmap displays notable advantages over these classical approaches: i) UV 13 
crosslinking is applied to living cells, thus mapping native protein-RNA interactions; ii) 14 
protein overexpression is not required, saving time and avoiding artifacts associated 15 
with overexpression; iii) it provides information on hundreds of RBPs at a time; iv) it 16 
can be applied to different experimental conditions and biological systems; and v) it is 17 
unbiased regarding the identity and boundaries of the RBD.   18 
More recently, Kramer et al. developed a sophisticated algorithm to identify peptides 19 
crosslinked to nucleotides by MS33. Applied to RNA interactome samples in 20 
Saccharomyces cerevisiae, this method uncovered 257 RNA-bound peptides in 124 21 
RBPs. While this approach provided bona fide RNA-binding sites with very high 22 
resolution, it suffers from a bias towards domains that crosslink particularly well, such 23 
as RRMs. Conversely, RBDmap reports RNA-binding sites at ~17 amino acids 24 
resolution by identification of unmodified neighboring peptides that are efficiently 25 
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detected by mass spectrometry, even when present in limited amounts. RBDmap 1 
identified 1174 RNA-interacting regions from 529 Hela cell RBPs, mapping equally to 2 
classical and non-canonical RBDs29. He et al. recently described an alternative 3 
method called RBR-ID35, which exploits the mass shift of peptides crosslinked to a 4 
nucleotide remnant in an indirect way. In brief, RBR-ID classifies peptide peaks with 5 
reproducibly lower intensity in UV irradiated samples than in non-irradiated controls as 6 
putative RNA-binding sites, assigning the loss of signal to the presence of crosslinked 7 
nucleotides that increase the peptide mass. RBR-ID complements RBDmap because 8 
it does not involve oligo(dT) selection and can thus assign RBDs to RBPs lacking 9 
association with polyadenylated RNAs. As a disadvantage, RBR-ID lacks a purification 10 
step to enrich for RBPs, which results in a highly complex mixture of peptides 11 
corresponding to the whole cell proteome. High variations in intensity of peptides with 12 
low abundance is a common phenomenon in highly complex samples and may yield 13 
a higher incidence of falsely positive results. As shown by in silico and experimental 14 
validation29, the two purification steps of RBDmap ensure that i) most of the peptides 15 
identified correspond to RBPs and ii) those enriched in the RNA-bound fraction 16 
actually map to RNA-binding sites. 17 
 18 
Limitations of the approach 19 
RBDmap will not be suitable to identify RBDs in the following scenarios: i) the RBP of 20 
interest is not active or not expressed under the experimental conditions employed; ii) 21 
the geometry of the protein-RNA interaction is not suitable for UV crosslinking, typically 22 
including RBDs that bind to double-stranded RNA; iii) the RBP binds exclusively to 23 
non-polyadenylated RNAs; iv) the LysC or ArgC (RBDpep) fragments crosslinked to 24 
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the RNA lack internal cleavage sites for trypsin, leading to a lack of MS-identifiable N-1 
link peptides; v) the available material is too limited (e.g. non-dividing primary cells).  2 
These limitations could be circumvented as follows. Prior to using RBDmap, we 3 
recommend employing available RNA and protein expression atlases to identify the 4 
cell type/line or the physiological conditions where the protein of interest is expressed. 5 
Alternatively, the protein can be expressed using transient transfection or stable cell 6 
lines to maximize the chances of obtaining an RBDmap profile. Overexpression may 7 
facilitate non-physiological interactions. However, RNA-binding profiles obtained 8 
under these conditions may still be informative and the identified RNA-binding sites 9 
can subsequently be validated in a more physiological context. Inefficient crosslinking 10 
of the protein of interest can be overcome by small scale set up experiments using 11 
RNA interactome capture followed by western blotting10. Different UV-crosslinking 12 
methods (PAR-CL or cCL), UV wavelengths (254, 312 or 360 nm35) and UV dosages 13 
can be tested to tailor the protocol to a given RBP. If the RBP does not bind to poly(A) 14 
RNA, RBDmap could potentially be combined with sequence-specific probes instead 15 
of oligo(dT) to capture its target RNA (if known)36-38. As discussed below, RBPs with 16 
suboptimal sequence for LysC and ArgC cleavage can be digested with alternative 17 
proteases (Figure 2B). We recommend analysis of the protein sequence and cross-18 
comparison with the known protease cleavage specificities prior to initiating an 19 
RBDmap experiment. Finally, limited starting material represents a challenge for 20 
RBDmap; however, new and more sensitive mass spectrometers are released every 21 
year. Sensitivity improvements will positively impact on the input requirements of 22 




Applications and future uses of the method 1 
RBDmap was developed as a method for the system-wide identification of RBDs in 2 
living cells. The current repertoires of RBDs identified from HeLa29 and HL-1 cells30 3 
can be expanded using other cell types and organisms to generate a catalogue of 4 
RBDs used by living systems. The successful implementation of RNA interactome 5 
capture in different cell lines (HeLa9, Huh-713, HEK2938, HL-130, RAW 26439, mouse 6 
embryonic stem cells11) and organisms (plants17-19, Drosophila melanogaster15,16, 7 
Caenorhabditis elegans14, Saccharomyces cerevisiae12-14 and Plasmodium 8 
falciparum20) expands the scope of biological systems where RBDmap can be readily 9 
employed. It can thus be used to study the evolution of RBDs across species to provide 10 
new insights into the evolution and regulation of eukaryotic RBDs. 11 
Moreover, RBDmap can further be adapted to focus on single RBPs by 12 
overexpressing the protein of interest in cultured cells to maximize protein coverage 13 
in RBDmap assays. Single protein applications can substitute the first oligo(dT) 14 
capture step by immunoprecipitation using antibodies against the protein of interest. 15 
This approach is complementary to conventional methods to map RBDs (see above), 16 
with the advantage of obtaining high resolution RNA-binding sites (~17 amino acids) 17 
without the need to generate a large repertoire of deletion or single point mutants.  18 
Notably, RBDmap can be applied to different physiological conditions to determine, in 19 
a global and comparative manner, whether the RNA-binding properties of RBDs 20 
respond to biological cues. Such studies could shed light on regulatory mechanisms 21 
controlling RNA binding and their links to altered cellular states (e.g. stress, 22 
differentiation, activation, division or apoptosis). Because RNA-binding sites heavily 23 
overlap with phosphorylation, acetylation and methylation sites29, it will be of great 24 
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interest to carry out such studies in parallel with proteome-wide analyses of 1 
posttranslational modifications performed under the same experimental conditions.  2 
These comparative analyses will shed light on the influence of posttranslational 3 
modifications in the regulation of RNA-binding. 4 
 5 
Experimental design 6 
Controls: the “RNA-bound” fraction eluted after the second round of oligo(dT) capture 7 
contains the protein fragments engaged in RNA binding (Figure 1). The supernatant 8 
of the second oligo(dT) capture contains the protein regions released from the RNA 9 
after the protease treatment, referred to here as “released” fraction (Figure 1). These 10 
two fractions are critical for the determination of RNA-binding sites, which are 11 
calculated using the peptide intensity ratios between the RNA-bound and the released 12 
fractions. RBDpeps are called by computational extension of the N-link peptide to the 13 
adjacent LysC or ArgC cleavage sites. The released fraction is thus a suitable negative 14 
control against which to test the intensities of every N-link peptide identified in the 15 
RNA-bound fraction. Because tryptic digestion is required to release the N-link peptide 16 
from the Lys/ArgC RBDpep, omitting trypsin will render no identifications in the RNA-17 
bound fraction. This potential control can be included at Step 33. Because of the lack 18 
of trypsin-derived neighboring peptides, MS identification in untreated control samples 19 
should be severely impaired by the presence of the nucleotide remnant crosslinked to 20 
the RBDpep.  21 
Optionally, a third fraction can be collected after the first round of oligo(dT) capture 22 
and protease treatment. This sample is referred to as “input” and closely corresponds 23 
to the RNA interactome10 with the addition of the LysC or ArgC proteolytic treatment. 24 
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Therefore, this control can serve a dual purpose: i) generate the repertoire of RBPs of 1 
the cell under study if not yet established, and ii) assess the influence of the protease 2 
of choice on the MS analysis. The input fraction is important in case of poor 3 
assignments of RNA-binding sites, since it can be used to test whether the first 4 
protease used is incompatible with the downstream tryptic digestion. Such an outcome 5 
will be reflected in the inefficient peptide identification in the input fraction because the 6 
peptides generated are too short.   7 
We recommend controls with a non-irradiated sample (noCL) to define the background 8 
as in10. Peptide intensity ratios between UV-irradiated versus non-irradiated sample in 9 
three independent biological replicates are analyzed, applying statistics (e.g. 10 
moderated t-test) to remove false positives. We recommend using a 1% FDR to 11 
minimize the occurrence of false positives, and for consistency with other RNA 12 
interactome studies.  13 
 14 
Number of cells. The modified protocol described here makes use of a substantially 15 
lower number of cells than in the original protocol10. Applied to HeLa cells, this 16 
workflow lead to the determination of an RNA interactome comparable in quantity and 17 
quality to the original study using 1/8 of starting material9,29. However, the number of 18 
cells required may vary when working with small cells or cells growing in suspension. 19 
 20 
Optimization of the protocol. A simplified protocol (from Step 1 to 14) using small-21 
scale settings can be used for optimization of the two key steps, UV crosslinking and 22 
oligo(dT) capture, to the cellular system or organism of interest. These set up 23 
experiments can be performed with only two 15 cm2 dishes per condition, allowing the 24 
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analysis of multiple parallel conditions in one experiment. RBP and RNA isolation can 1 
be monitored using silver staining (Figure 2C), western blotting, RT-qPCR or 2 
bioanalyzer as in10. In small-scale experiments, RNA isolation is performed with 400 3 
µl of bead slurry, using 1.8 ml of lysis and wash buffers and 200 µl of elution buffer per 4 
oligo(dT) capture round (replacing volumes from Step 1 to 14). Silver staining should 5 
yield a complex protein pattern applying cCL or PAR-CL, whereas non-irradiated 6 
samples are expected to be devoid of proteins. Known RBPs are expected to be 7 
enriched in irradiated samples and absent in non-irradiated controls9,10. Negative 8 
controls (e.g. ß-actin and histone 3 and 4) should be absent in all eluates irrespective 9 
of the UV irradiation. A successful experiment should lead to at least 10 fold 10 
enrichment of mRNA over rRNA by RT-qPCR measurements9,10. As a rule of thumb, 11 
the UV dosage that promotes the most efficient capture of RBPs without affecting RNA 12 
integrity is optimal.  13 
 14 
The protocol described here is tailored to adherent cells. For suspension cells, we 15 
recommend using a modified protocol where first cells are collected by low speed 16 
centrifugation, followed by resuspension of the cell pellet in 1 ml of PBS. The cell 17 
suspension is then transferred to a 10 cm dish and homogeneously distributed across 18 
the dish surface. The dish is subsequently placed on ice without the lid and irradiated 19 
as in Step 3. Cells are then lysed by addition of 2x lysis buffer (40 mM Tris HCl pH 20 
7.5, 1M LiCl, 1% LiDS (wt/v, stock 10%), 2 mM EDTA, 10 mM DTT). For fragile cells 21 
or cells with poor adherence, we recommend avoiding PBS washes prior to UV 22 
irradiation (Step 2). Instead, we obtained optimal RNA interactome and RBDmap 23 
results when we omitted phenol red from the standard DMEM medium (unpublished 24 
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data, AC). Under these conditions, cells can be directly irradiated with UV after 1 
removal of the media.  2 
In the present protocol, we used both cCL and PAR-CL in parallel to maximize the 3 
identification of RNA-binding sites. However, users may favor one crosslinking 4 
approach over the other due to technical limitations of the model system (e.g. limited 5 
4SU incorporation in complex organisms or non-dividing cells) or due to prior 6 
information regarding the protein of interest (e.g. the RBP crosslinks more efficiently 7 
either with cCL or PAR-CL9).  8 
Choice of protease. Once the first part of the protocol is established in the model 9 
system of choice, the next step is to choose the protease to use in Step 16. In our 10 
initial study, we used ArgC and LysC because of their i) compatibility with the 11 
downstream trypsin treatment, ii) suitability for proper digestion of most RBPs (~17 aa 12 
peptide fragments on average) and iii) experimentally proven efficiency in MS studies. 13 
However, these proteases are only suitable to generate RBD profiles of a substantial 14 
subset of the RNA interactome9,29. When studying a particular RBP, we recommend 15 
analyzing its sequence to identify the most suitable protease for RBDmap. As a 16 
reference, the protease of choice should generate fragments of about 20 aa length on 17 
average and contain internal tryptic peptides. Generation of longer proteolytic 18 
fragments will affect the RBD resolution, while shorter fragments may negatively affect 19 
the MS identification, because the probability to encounter an optimal trypsin cleavage 20 
site within the fragment will be reduced. For example, we followed an in silico approach 21 
analyzing the protein sequences of the HeLa mRNA interactome9 to generate a set of 22 
predicted in silico proteolytic fragments for each of the ten proteases commonly used 23 
in proteomics (Figure 2B) (Supplemental Methods, page 1). We then mapped the 24 
tryptic peptides experimentally identified in the HeLa RNA interactome to these 25 
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fragments as an estimate of the expected peptide coverage9. Each tryptic peptide was 1 
extended in silico to the closest protease cleavage sites to reconstitute the expected 2 
peptide fragments. We set an arbitrary RNA-binding site at the center of each protein 3 
and determined the number of proteins for which a given protease would cover the 4 
RBD with a peptide shorter than 20% of the actual protein length. This analysis 5 
revealed LysC and ArgC as the most suitable proteases for RBDmap experiments. 6 
Nevertheless, other proteases such as AspN, chymotrypsin and glutamyl 7 
endopeptidase also deserve consideration (Figure 2B). If interested in a particular 8 
protein or protein family, we recommend performing similar in silico or manual 9 
sequence analyses to determine the most suitable protease. 10 
The next important step is to determine the optimal amount of protease required to 11 
minimize the incidence of miscleavages. Figure 2D shows a protease calibration 12 
experiment in which we divided the eluate of a RNA interactome capture from five 500 13 
cm2 dishes into five tubes and tested different LysC concentrations (from 0.5 to 3 µg) 14 
and incubation temperatures (37°C and 22°C). Incubation with 1 µg of LysC at 37°C 15 
is sufficient to fully disrupt the protein pattern observed in untreated cells, suggesting 16 
that proteins are efficiently proteolyzed. Indeed, no polypeptides (except the protease 17 
itself) are detected in a 15% acrylamide gel, indicating that the protease cleaves the 18 
RBPs into small peptides that run out the gel (Figure 2D). By contrast, treatment with 19 
3 µg of LysC for 16h at 22°C does not promote complete cleavage of purified RBPs. 20 
MS analyses of RNA interactome capture eluates treated with the experimentally 21 
determined concentrations of LysC and ArgC revealed that both proteases generate 22 
peptides of about 17 amino acids on average and that the number of missed cleavages 23 
is negligible29. Importantly, RNA is massively degraded when the protease is not 24 
added to the digestion mix, suggesting the presence of contaminant RNases that 25 
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damage the sample in extended incubations at 37°C (Figure 2E). However, protease 1 
treatment prevents RNA degradation, probably by proteolytic cleavage of the RNases. 2 
We nevertheless add RNase inhibitors to prevent any potential RNA degradation that 3 
may still occur immediately after protease addition. 4 
 5 
The two rounds of oligo(dT) capture. The first purification using oligo(dT) is 6 
performed with cell lysates and is designed to remove all non-covalent RNA interactors 7 
using high salt (500 mM LiCl) and ionic detergents (0.5% LiDS). In contrast, the second 8 
round of oligo(dT) capture is designed to separate the peptide pool that remains 9 
covalently bound to RNA after the first protease treatment from the pool of peptides 10 
that is released into the supernatant. Because the supernatant will be directly analyzed 11 
by MS to identify the released peptides, we recommend avoiding the use of MS-12 
incompatible detergents such as LiDS or NP-40 (igepal) in the hybridization buffer. 13 
Subsequent washes containing high salt concentrations and the ionic detergent LiDS 14 
prevent co-purification of contaminant released peptides via non-covalent interactions 15 
with the RNA or with the peptides crosslinked to it. In addition, these washes increase 16 
the dilution factor, minimizing the contamination of the RNA-bound fraction with highly 17 
abundant released peptides. The second oligo(dT) capture step is performed in a 18 
significantly lower volume (2 ml vs 25 ml) to facilitate the downstream sample 19 
preparation for MS and to maximize the capture of the RNA. We thus adjusted the 20 
amount of beads in the second oligo d(T) selection step to maintain the volume to 21 




Protease digestion. To optimize the protease treatment, we recommend incubating 1 
the eluates from Step 14 with increasing concentrations of protease and selecting the 2 
minimal concentration to fully disrupt the protein pattern observed by silver staining 3 
(Figure 2D). As a necessary control for RBDmap assays, we recommend to collect 4 
aliquots prior to and after protease treatment to monitor protein and RNA integrity by 5 
silver staining and bioanalyzer (Figure 2D-G). The sample should be used for the 6 
second oligo(dT) capture only if the protease digestion appears complete. We noticed 7 
extensive RNA degradation when incubating the samples for 8 hours at 37°C in 8 
absence of protease, suggesting the presence of contaminating RNases (Figure 2E). 9 
We thus recommend supplementing the extracts with RNase inhibitors (e.g. RNase-10 
In) to protect the RNA from degradation during the early steps of the protease 11 
treatment, when RNases are still intact. After longer incubations both the RNases and 12 
the RNase inhibitor will be hydrolyzed by the protease. 13 
Mass spectrometry. We used dimethyl labeling40 for quantitative proteomic analysis, 14 
employing a platform coupling nano-flow UPLC to a mass spectrometer with MS/MS 15 
capability, such as the quadrupole-time-of-flight or Orbitrap instrument (e.g., similar 16 
to41). To maximize the depth of peptide identification and reduce sample complexity, 17 
we used isoelectric focusing pre-analytically to generate 12 peptide fractions. Note 18 
that the number of fractions can be adjusted according to sample complexity and the 19 
total amount of peptides available. Each fraction is then analyzed by high-resolution 20 
nano-LC-MS/MS in data-dependent acquisition mode. A critical point in RBDmap is its 21 
quantitative power, and we successfully applied stable-isotope dimethyl labeling to 22 
quantify the peptides in input samples as well as in the RNA-bound and released 23 
fractions29,30. Note that this protocol is also compatible with other chemical labeling 24 
strategies, such as iTRAQ42 or TMT43. In principle, label-free quantification is also 25 
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capable to provide quantitative information on peptide abundance, however, we 1 
recommend to apply a chemical labeling strategy to avoid problems with intensity 2 
normalization between RNA-bound and released samples. 3 
HPLC and MS parameters. Typically, 90-120 min linear gradients from 5-35% solvent 4 
B are sufficient for optimal peptide separation. A longer 4h gradient would be advisable 5 
in cases where no peptide fractionation is performed. Other MS/MS-parameters are 6 
instrument- and vendor-specific and should be optimized for the maximum number of 7 
peptide identifications. We found that the standard settings commonly used in 8 
proteomic applications provide a good starting point, and usually allow satisfactory 9 
analyses. Mass spectrometric raw data can be analyzed with any standard free (e.g. 10 
MaxQuant44) or commercial software tools that allow peptide identification and provide 11 
peptide-level quantitative data. 12 
MS data analysis. We processed the raw data using MaxQuant (version 1.3.0.5)44. 13 
MS/MS spectra should be searched against the appropriate UniProt database linked 14 
to a database containing common contaminants. For identification, we recommend to 15 
set the enzyme specificity to trypsin/P, allowing a maximum of two missed cleavages. 16 
We allowed cysteine carbamidomethylation as fixed modification and methionine 17 
oxidation and protein N-terminal acetylation as variable modifications, while the 18 
minimal peptide length was set to six amino acids. The mass tolerances were set to 19 
20 ppm for the first search, 6 ppm for the main search, and 0.5 Da for product ion 20 
masses. We applied a 1% FDR for both peptide and protein identification. 21 
Computational assignment of RBDs. Peptides identified by MS can be analysed 22 
using the statistical programming language R and the packages RBDmap, 23 
RBDmapHeLa, and mRNAinteractomeHeLa described in9,29. A detailed analytical 24 
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pipeline is provided in Supplementary Methods. Briefly, a simulation of tryptic peptides 1 
can optionally be performed to assess suitability of different proteases for the protein/s 2 
of interest (Supplementary Methods, section 2, pages 1-5). Peptide identifications and 3 
quantifications by MaxQuant are first mapped to a reference human proteome 4 
annotation that includes information on protein and gene identifiers, protein domains, 5 
and other regions (Supplementary Methods, sections 3-4, pages 6-10). Proteins 6 
enriched in the UV-irradiated over the non-irradiated input sample with a 1% FDR are 7 
classified as RBPs. To identify the RNA binding regions, the ratio between the intensity 8 
of each identified peptide in the RNA-bound and released fraction is computed 9 
(Supplementary Methods, section 5, pages 10-11). Statistical significance is 10 
determined by a moderated t-test corrected for multiple testing with Benjamini-11 
Hochberg (Supplementary Methods, section 6, pages 11-16). Peptides enriched in the 12 
RNA-bound over the released fractions with 1% FDR are classified as RBDpeps and 13 
those enriched with a 10% FDR are catalogued as “CandidateRBDpep” (i.e. potential 14 
RNA-binding region). Peptides are then extended to their adjacent LysC and ArgC 15 
cleavage sites to recall the original proteolytic fragments, only if the tryptic peptide is 16 
uniquely mapped to a single protein (Supplementary Methods, section 7, pages 16-17 
17). Proteolytic fragments are displayed in individual protein plots together with the 18 
domain information (Supplementary Methods, section 8, pages 17-19). Finally, an html 19 
report summarizing the analysis is generated (Supplementary Methods, section 9, 20 
pages 19-20). 21 
 22 
Reagents 23 
x 4-Thiouridine (4SU) (Sigma-Aldrich, cat. no. T4509). 24 
20 
 
x Acetonitrile, HPLC grade (Merck Millipore, cat. no. 1000302500) 1 
x Amicon Ultra® Centrifugal Filters (15 ml and 500 µl, 3KDa cut off, Millipore cat. no. 2 
UFC900324 and UFC500396). CAUTION! Equilibrate the filter unit following the 3 
manufacturer’s instructions before use.  4 
x Calcium chloride (CaCl2) (Sigma-Aldrich, C5670). 5 
x Complete EDTA-free proteinase inhibitor cocktail (Roche, cat. no. 11873580001). 6 
x DMEM with 4.5 mg l−1 D-glucose (Sigma-Aldrich, cat. no. D0422). 7 
x Endoproteinase ArgC Sequencing Grade (Promega, cat. no. V1881) 8 
x Endoproteinase Lys-C (Wako, cat. no. 129-02541). 9 
x Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, cat. no. E6758).  10 
x Dimethylsulfoxide (DMSO) (Merck Millipore, 102952). 11 
x Di-sodium hydrogen phosphate (Na2HPO4) (Merck, cat. no. 1.06580). 12 
x Dithiothreitol (DTT) (Biorad, 161-0611). 13 
x Formaldehyde (CH2O) (37% (vol/vol), (Sigma-Aldrich, cat. no. 252549). 14 
! CAUTION. Formaldehyde solutions and formaldehyde vapors are toxic, 15 
prepare solutions in a fume hood. 16 
x Formaldehyde (CD2O) (20%, 98% D, Isotec, cat. no. 492620). 17 
! CAUTION. Formaldehyde solutions and formaldehyde vapors are toxic, 18 
prepare solutions in a fume hood. 19 
x Formaldehyde (13CD2O) (20%, 99% 13C, 98% D, Isotec, cat. no. 596388). 20 
! CAUTION. Formaldehyde solutions and formaldehyde vapors are toxic, 21 
prepare solutions in a fume hood. 22 
x Formic acid, UHPLC grade (Sigma-Aldrich, cat. no. 14265). 23 
x Glutamine (Gibco, cat. no. G7513). 24 
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x HeLa (American type culture collection (ATCC), cat. no. CCL-2). Maintain the cells 1 
at 37°C in a humidified atmosphere containing 5% CO2.  2 
CAUTION: The cell lines used in your research should be regularly checked to 3 
ensure they are authentic and are not infected with mycoplasma. 4 
x Heat inactivated fetal bovine serum (Gibco, cat. no. 10500064). 5 
x Huh-7 cells (ATCC cat. no. HB-8064). Maintain the cells at 37°C in a humidified 6 
atmosphere containing 5% CO2. 7 
 CAUTION: The cell lines used in your research should be regularly checked to 8 
ensure they are authentic and are not infected with mycoplasma. 9 
x Iodoacetamide (Biorad, cat. no. 163-2109). 10 
x Lithium chloride (LiCl) (Sigma, cat. no. 62476). 11 
x Lithium dodecyl sulfate (LiDS) (Sigma-Aldrich, cat. no. L9781). 12 
x Oligo (dT25) magnetic beads (New England Biolabs, cat. no. S1419S). 13 
x Penicillin-streptomycin (Sigma-Aldrich, cat. no. P0781). 14 
x Phosphate-buffered saline (PBS) tablet (Sigma-Aldrich, cat. no. P4417). 15 
x Ribonuclease A from bovine pancreas (RNase A) (Sigma-Aldrich, cat. no. R4642). 16 
x Ribonuclease T1 from Aspergillus oryzae (RNase T1) (Sigma-Aldrich, cat. no. 17 
R1003). 18 
x RNase-In (Promega, cat. no. N2511). 19 
x SilverQuestTM, kit for silver staining (Invitrogen, cat. no. LC6070). 20 
x Sodium chloride (NaCL) (Sigma-Aldrich, cat. no. S7653). 21 
x Sodium cyanoborohydride (NaBH3CN) (Fluka, cat. no. 71435). 22 
x Sodium cyanoborodeuteride (NaBD3CN) (96% D, Isotec, cat. no. 190020). 23 
x Sodium dihydrogen phosphate (NaH2PO4) (Merck, cat. no. 1.06346). 24 
x StageTips, C18 material, 200µL tip (Thermo Fisher Scientific, cat. No. SP301). 25 
22 
 
x Triethylammoniumbicarbonate (TEAB)  (Sigma-Aldrich, cat. no. T7408). 1 
x Trypsin Gold, Mass Spectrometry Grade (Promega, cat. no. V5280).  2 
x Urea (Biorad, cat. no. 161-0745-MSDS). 3 
 4 
Equipment  5 
x 500 mm2 square dishes (Nunclon, cat. no.  166508). 6 
x Class II biosafety cabinet.  7 
x Crosslinking devices: cCL = 254 nm bulbs; PAR-CL= 365 nm bulbs. 8 
Spectrolinker UV Crosslinkers (Spectroline cat. no. XL-1500 and XL-1500A, 9 
respectively). 10 
x GP Millipore express plus 500 ml funnel (Millipore, cat. no. SCGPT05RE) 11 
x Humidified 37°C, 5% CO2 incubator. 12 
x Magnetic Separation Rack (50 ml NEB, cat. no. S1507S; 15 ml, Permagen; 2 13 
ml, NEB cat. no. S1509S or DynaMag-2, cat. no.  123.21D, Invitrogen). 14 
x Nano-UPLC system (e.g. EASY-LC 1000 or similar; Waters nanoAcquity or 15 
similar), capable of operating at a flow rate of 100-300 nl/min at a pressure of 16 
up to 1000 bar. 17 
x Needle (27G, 3/4-inch; no. 20, 0.4 mm × 19 mm; BD Microlance; cat. no. 18 
302200). 19 
x Refrigerated Bench-top centrifuge. 20 
x RNA 6000 Pico Bioanalyzer Chip and reagents (Agilent technologies, cat. no. 21 
5067-1513 and 5067-151). 22 
x Software for protein identification by database searching, e.g. Mascot 23 
(MatrixScience), Sequest (Thermo) or Andromeda45 (via MaxQuant44). 24 
x Syringes (5 ml; luer lock; Medicine, ref: IVL05). 25 
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x Tandem Mass Spectrometer (e.g. Thermo Scientific Orbitrap Fusion, Q-1 
Exactive or similar; Bruker Impact II or similar). 2 
x MaxQuant software44 (or similar) and R/bioconductor package limma46. A 3 
detailed analysis pipeline can be found in the Supplementary methods. 4 
x RBDmap, RBDmapHeLa, and mRNAinteractomeHeLa R packeges9,29 5 
 6 
Reagent setup 7 
x  (1M) DTT. Divide the stock of (1M) DTT into 5 ml aliquots and store at -20°C 8 
for 1 year.  9 
CRITICAL: DTT is used to minimize the contamination of indirect RNA 10 
interactors forming disulfide bridges with the actual RBP. 11 
x 4-Thiouridine. Prepare 1 ml of a 100 mM stock solution in water and divide it 12 
into 50 µl aliquots. Protect the solution from light by covering the tube with 13 
aluminum foil and storing the aliquots into an opaque box at -20°C for 1 year.  14 
x Oligo(dT) magnetic beads equilibration and recycling. To equilibrate the beads, 15 
wash them three times with 3 volumes of lysis buffer and incubate for 5 min 16 
with gentle rotation between washes. To recycle the beads between capture 17 
rounds, add 1ml of 0.1 NaOH to the pellet. Resuspend the beads vigorously 18 
and incubate for 3 min at 55°C with agitation in a thermomixer. Collect the bead 19 
pellet with a magnet and wash 3 times with 1.5 ml of PBS supplemented with 20 
0.025% NP-40 prior to adding them again to the lysate. Beads can be recycled 21 
up to three times.  22 
x Lysis buffer.  20 mM Tris HCl pH 7.5, 500 mM LiCl, 0.5% LiDS (wt/vol, stock 23 
10%), 1 mM EDTA, 5 mM DTT. Autoclave to inactivate contaminants such as 24 
proteases that may potentially interfere with RBDmap. After cooling, complete 25 
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the buffer by addition of filtered LiDS. DTT should be added immediately before 1 
usage. Can be stored for up to 3 months at 4°C.  2 
CRITICAL: We typically generate 1l and then aliquot into 200 ml bottles 3 
(equivalent to the volume required for one large-scale experiment). By doing 4 
so, we noticed a reduction in contaminations due to handling (e.g. RNases, 5 
proteases, keratins, etc). CRITICAL: We do not observe traces of RNA 6 
degradation when combining EDTA and the denaturing agent LiDS in the lysis 7 
buffer. 8 
x Buffer 1. 20 mM pH 7.5 Tris HCl, 500 mM LiCl, 0.1% LiDS (wt/vol), 1 mM EDTA, 9 
5 mM DTT. Autoclave to inactivate contaminants such as proteases that may 10 
potentially interfere with RBDmap. After cooling, complete the buffer by addition 11 
of filtered LiDS. DTT should be added immediately before usage. Can be stored 12 
for up to 3 months at 4°C. CRITICAL: We typically generate 1l and then aliquot 13 
into 200 ml bottles (equivalent to the volume required for one large-scale 14 
experiment). By doing so, we noticed a reduction in contaminations due to 15 
handling (e.g. RNases, proteases, keratins, etc). 16 
x Buffer 2. 20 mM pH 7.5 Tris HCl, 500 mM LiCl, 1 mM EDTA, 5 mM DTT, 0.01% 17 
NP40/Igepal (vol/vol). Autoclave to inactivate contaminants such as proteases 18 
that may potentially interfere with RBDmap. DTT should be added immediately 19 
before usage. Can be stored for up to 3 months at 4°C. CRITICAL: We typically 20 
generate 1l and then aliquot into 200 ml bottles (equivalent to the volume 21 
required for one large-scale experiment). By doing so, we noticed a reduction 22 
in contaminations due to handling (e.g. RNases, proteases, keratins, etc). 23 
x Buffer 3. 20 mM pH 7.5 Tris HCl, 200 mM LiCl, 1 mM EDTA, 5 mM DTT. 24 
Autoclave to inactivate contaminants such as proteases that may potentially 25 
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interfere with RBDmap. DTT should be added immediately before usage. Can 1 
be stored for up to 3 months at 4°C. CRITICAL: We typically generate 1l and 2 
then aliquot into 200 ml bottles (equivalent to the volume required for one large-3 
scale experiment). By doing so, we noticed a reduction in contaminations due 4 
to handling (e.g. RNases, proteases, keratins, etc). 5 
x Elution buffer. 20 mM pH and 7.5 Tris HCl. Autoclave to inactivate contaminants 6 
such as proteases that may potentially interfere with RBDmap. Can be stored 7 
for up to 3 months at 4°C. 8 
x 5x Hybridization buffer. 100 mM Tris HCl pH 7.5, 2.5 M LiCl, 1 mM EDTA, 25 9 
mM DTT. Autoclave to inactivate contaminants such as proteases that may 10 
potentially interfere with RBDmap. DTT should be added immediately before 11 
usage. Can be stored for up to 3 months at 4°C. CRITICAL: We typically 12 
generate 1l and then aliquot into 200 ml bottles (equivalent to the volume 13 
required for one large-scale experiment). By doing so, we noticed a reduction 14 
in contaminations due to handling (e.g. RNases, proteases, keratins, etc). 15 
x Buffer 4. 10 mM pH 7.5 Tris HCl, 50 mM NaCl. Autoclave to inactivate 16 
contaminants such as proteases that may potentially interfere with RBDmap. 17 
Can be stored for up to one year at room temperature (22 to 25°C). 18 
x 5X proteinase K buffer. 50 mM pH 7.5 Tris HCl, 750 mM NaCl, 1% SDS (wt/vol), 19 
50 mM EDTA, 2.5 mM DTT, 25 mM CaCl2. Autoclave to inactivate 20 
contaminants such as proteases that may potentially interfere with RBDmap. 21 
DTT should be added immediately before usage. Can be stored for up to one 22 
year at room temperature (22 to 25°C). 23 
x 10X ArgC buffer. 8M urea, 250 mM 7.5 Tris HCl, 25 mM CaCl2, 25 mM DTT. 24 
Autoclave to inactivate contaminants such as proteases that may potentially 25 
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interfere with RBDmap. DTT should be added immediately before usage. Use 1 
freshly made.  2 
CRITICAL: Always prepare urea-based buffers (ArgC buffer) freshly on the day 3 
of use. Aqueous urea can degrade to isocyanic acid which can react with 4 
proteins, hampering data analysis.  5 
Mass spectrometry buffers 6 
x 50 mM TEAB. 500 µL of 1M Triethylammoniumbicarbonate in 10 mL water. Store 7 
at 4°C for 1 year. 8 
x 1M DTT. 154 mg Dithiothreitol in 1 ml water. 9 
CRITICAL: Can be aliquoted and stored at -20°C for 1 year.  10 
x 1M IAA. 185 mg Iodoacetamide in 1 ml water. 11 
CRITICAL: prepare freshly and use within a day. Protect from light. 12 
x 0.5 M NaCl. 29.2 mg Sodium chloride in 1 mL water. Store at room temperature 13 
(RT) indefinitely. 14 
x 50 mM NaH2PO4: 6.9 g in 1 l water. Store at 4°C for 1 year. 15 
x 50 mM Na2HPO4: 8.9 g in 1 l water. Store at 4°C for 1 year. 16 
x 50 mM sodium phosphate buffer pH 7.5 (for 9 ml mix 2 mlof 50 mM NaH2PO4 with 17 
7 ml of 50 mM Na2HPO4). Store at 4°C for 1 year. 18 
x light labeling reagent: for 1 ml mix 900 µl 50 mM sodium phosphate buffer with 50 19 
µl 4% (vol/vol) formaldehyde in water and 50 µl 0.6 M cyanoborohydride 20 
(NaBH3CN). Prepare freshly on the day of use and keep at 4°C until use, do not 21 
store for more than 24h. 22 
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x medium labeling reagent: for 1 mL mix 900 µl 50 mM sodium phosphate buffer with 1 
50 µl 4% (vol/vol) D2-formaldehyde (CD2O) in water and 50 µl 0.6 M 2 
cyanoborohydride (NaBH3CN). Prepare freshly on the day of use and keep at 4°C 3 
until use, do not store for more than 24h. 4 
x heavy labeling reagent: for 1 ml mix 900 µl 50 mM sodium phosphate buffer with 5 
50 µl 4% (vol/vol) 13C,D2-formaldehyde (13CD2O) in water with 50 µl 0.6 M 6 
cyanoborodeuteride (NaBD3CN). Prepare freshly on the day of use and keep at 7 
4°C until use, do not store for more than 24h. 8 
x Buffer A: 1% (vol/vol) formic acid in water. Store at room temperature (RT) 9 
indefinitely. 10 
x Buffer B: 1% (vol/vol) formic acid in 80% acetonitrile. Store at room temperature 11 
(RT) indefinitely. 12 
x MS-Buffer: 5% (vol/vol) DMSO, 1% (vol/vol) formic acid in water. Store at room 13 
temperature (RT) indefinitely. 14 
PROCEDURE  15 
Cell culture TIMING overnight  16 
1. Seed HeLa cells on 8 x 500 cm2 (4000 cm2 of total growth area) dishes at a 17 
confluence of 40%. Incubate the cells overnight in normal medium (DMEM and 18 
5% fetal calf serum, FCS) to reach 80% confluence after 16 h (~2x107 cells per 19 
dish). Label half of the dishes with 4SU (i.e. four) for PAR-CL and keep the 20 
other half unlabeled (i.e. four) (Figure 3). To label the RNAs with the 21 
photoactivatable nucleotide analogue for PAR-CL, supplement the medium 22 
with 100 μM 4SU and incubate overnight. Separate one 4SU-labeled and one 23 
unlabeled dish to be used as non-irradiated negative control. Use three 4SU-24 
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labeled and three unlabeled dishes for PAR-CL and cCL, respectively (Figure 1 
3).  2 
? TROUBLESHOOTING 3 
CAUTION The cell lines used in your research should be regularly checked to 4 
ensure they are authentic and are not infected with mycoplasma. 5 
CRITICAL STEP: (Optional) To test 4SU incorporation, a small scale (see 6 
adaptation) experiment using only PAR-CL is performed. 4SU-labeled poly(A) 7 
RNA present in oligo(dT) eluates is purified via 4SU-dependent biotinylation 8 
followed by streptavidin purification as described elsewhere47,48. Proportion of 9 
labeled RNA will be defined by comparing the amount of RNA in the eluates of 10 
the streptavidin purification with that remaining in the supernatant.  11 
 12 
Preparation for UV-crosslinking TIMING ~30 min 13 
2. Wash cells twice with 15 ml of PBS (room temperature, RT).  14 
CRITICAL STEP: we noticed that residual DMEM can induce variability in 15 
crosslinking efficiency across experiments. We recommend removing carefully 16 
the excess of DMEM by tilting the dish and handling the 4SU-labeled non-17 
irradiated control in a darkened room to avoid potential crosslinking mediated 18 
by natural light.  19 
UV-crosslinking TIMING ~30 min (whole sample set) 20 
3. Remove the PBS and place the culture dishes after removing their lids on ice 21 
immediately before crosslinking at a distance of ~15-20 cm from the UV source. 22 
Irradiate with 0.15 J/cm2 (~25-50 sec) with UV light at 254 nm for cCL or at 365 23 
nm for 4SU-labeled cells (PAR-CL).  24 
? TROUBLESHOOTING 25 
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CRITICAL STEP: Pre-heat the UV bulbs (both 365 nm and 254 nm) by running 1 
a 0.5 J/cm2 program immediately before starting the irradiation of the dishes. 2 
This step will make the intensity of the UV bulbs comparable across irradiation 3 
steps (i.e. similar J/cm2 per second).   4 
CRITICAL STEP: It is important to process the cells quickly from Step 3 to Step 5 
5; therefore, if dealing with a large number of dishes, proceed with small sub-6 
sets (about 1-3 dishes) at a time, while leaving the remaining dishes in culture. 7 
Non-irradiated controls should be processed last and kept in the incubator while 8 
working with the dishes treated with UV light.  9 
 10 
Lysis TIMING ~15 min 11 
4. For RNA bound/released fractions (two dishes of cCL and two dishes of PAR-12 
CL; Figure 3): Add 10 ml of lysis buffer to one plate irradiated with UV light at 13 
254 nm and harvest the cells with a rubber policeman. Transfer the 10 ml of 14 
lysate to the other plate irradiated with UV at the same wavelength and harvest 15 
the cells. Transfer these 10 ml of lysate to a 50 ml Falcon tube. Add 10 ml of 16 
fresh lysis buffer to one dish irradiated with 365 nm UV light and harvest the 17 
cells. Transfer the 10 ml of lysate to the second dish irradiated at the same 18 
wavelength and harvest the cells. Add these 10 ml to the same 50ml Falcon 19 
tube and mix with a 25 ml pipet. Adjust the volume to 25 ml using fresh lysis 20 
buffer. 21 
 For the input fractions (one dish of noCL, one dish of 4SU-labeled noCL, one 22 
dish of cCL and one dish of PAR-CL; Figure 3). Add 10 ml of lysis buffer to a 23 
dish irradiated at 254 nm and harvest the cells. Transfer these 10 ml to the dish 24 
irradiated at 365nm and harvest the cells. Transfer the lysate to a 15 ml Falcon 25 
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tube and adjust the volume to 12 ml. Repeat the same process with the dishes 1 
that were not UV-exposed, transferring the lysate to a new tube.  2 
At this stage we have 1x50 ml tube with 25 ml of lysate for the RNA-bound and 3 
released fractions, and 2x15 ml tubes with 12 ml of lysate from irradiated and 4 
non-irradiated cells for the input fractions. 5 
     6 
Homogenization TIMING ~30 min 7 
5. Pass each sample three times through a syringe with a narrow needle (gauge 8 
0.4mm diameter) to homogenize. Incubate the lysates for 10 min at 4°C.  9 
CRITICAL STEP The bigger the syringe, the more difficult it is to pass the lysate 10 
through the narrow needle. We recommend using 5 ml syringes and transferring 11 
the lysate from one tube to a new one stepwise until the homogenization has 12 
been completed. The lysate should be passed through the needle quickly to be 13 
appropriately homogenized. If the sample is not completely homogeneous after 14 
3 cycles, repeat as many times as needed, and do not proceed to the next step 15 
until the homogenization is satisfactory (i.e. viscosity is significantly reduced 16 
when inverting the tube and the sample looks homogeneous).    17 
 18 
? TROUBLESHOOTING  19 
PAUSE POINT Samples can be frozen at -80°C for up to one month. 20 
Nevertheless, we recommend avoiding repeated freeze-thawing cycles. If 21 
possible, proceed to Step 6 without freezing.  22 
 23 
First oligo(dT) capture TIMING ~6h 24 
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6. Add 3 ml and 1.5 ml of previously equilibrated oligo(dT)25 magnetic beads (see 1 
Reagent Setup) to the 50 ml and 15 ml falcon tubes, respectively. Incubate for 2 
1 h at 4°C with gentle rotation. Place the tubes onto a magnet at 4°C and wait 3 
until the beads are completely captured. This process should take 2-10 min. 4 
Incomplete homogenization may explain longer times. Recover the 5 
supernatants and store them in new tubes at 4°C for the other two cycles of 6 
oligo(dT) capture (see Step 13).  7 
7. Resuspend the beads in 25 ml and 12 ml of ice-cold lysis buffer for the 50 ml 8 
and the 15 ml tubes, respectively. Incubate for 5 min at 4°C with gentle rotation, 9 
pellet the beads with the help of a magnet. Remove and discard the 10 
supernatant.   11 
CRITICAL STEP: We recommend resuspending the beads first in a small 12 
volume (4 and 2 ml of lysis buffer for the 50 ml and the 15 ml tubes, respectively) 13 
by vigorously pipetting up and down using a p1000 pipet. When satisfied with 14 
the resuspension, add lysis buffer to reach 25 ml and 12 ml, respectively. 15 
Repeat this process in Steps 8-10.   16 
8. Add 25 ml and 12 ml of ice-cold buffer 1 for the 50 ml and 15 ml tubes, 17 
respectively. Resuspend the beads and incubate for 5 min at 4°C with gentle 18 
rotation. Pellet the beads using the magnet and discard the supernatant.  19 
Repeat this step once (i.e. two washes with buffer 1). 20 
CRITICAL STEP: Note that when the mRNA-protein complexes are efficiently 21 
isolated, a halo surrounding the bead pellet will be noticeable during the first or 22 
second wash with this buffer only in the UV crosslinked samples10.    23 
9.  Add 25 ml and 12 ml of ice-cold buffer 2 to the 50 ml and 15 ml tubes, 24 
respectively. Resuspend the beads and incubate for 5 min at 4°C with gentle 25 
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rotation. Pellet the beads using the magnet and discard the supernatant. 1 
Repeat this step once (i.e. two washes with buffer 2). 2 
10. Add 25 ml and 12 ml of buffer 3 at room temperature to the 50 ml and 15 ml 3 
tubes, respectively. Resuspend the beads vigorously. Pellet the beads using 4 
the magnet and discard the supernatant. Repeat this step once (i.e. two 5 
consecutive washes with buffer 3). 6 
CRITICAL STEP: We noticed bead loss occurring at this step following 7 
incubation with buffer 3 for too long. We thus recommend avoiding the 5 min 8 
incubation performed in the previous steps and placing the tube in the magnet 9 
immediately after resuspending the beads.  10 
11. For elution, resuspend the beads in 500 μl or 250 μl of elution buffer for the 50 11 
ml and 15 ml tubes, respectively, and transfer the bead suspensions to a low-12 
binding, 2 ml tube. Incubate for 3 min at 55°C with agitation (~500 rpm in a 13 
thermomixer). Pellet the beads using the magnet and transfer the supernatant 14 
to a new tube. Beads can be recycled at this point as indicated in Reagent 15 
Setup. Determine the RNA concentration in eluates using a Nanodrop device. 16 
CRITICAL STEP: (Optional) To ensure that the eluate is fully depleted of 17 
magnetic beads, we recommend placing the eluates on the magnet for 3 min 18 
at 4°C. Collect the supernatant again and transfer it to a new tube prior to 19 
measuring the RNA concentration in a Nanodrop device.  20 
12. Repeat Steps 7 to 11 twice more to deplete samples of poly(A) RNAs. We 21 
recommend reusing the oligo(dT) beads up to three times – to do so, treat the 22 
beads as described in Reagent Setup. Then add them back to the lysate 23 
separated in Step 7. 24 
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CRITICAL STEP. Do not re-use the beads from one “condition” for other 1 
conditions (e.g. beads used for crosslinked samples should not be used for non-2 
irradiated controls) to avoid cross-contamination.  3 
13. Pool the eluates from the three successive cycles of poly(A)+ RNA capture (final 4 
volume 1.5 ml for RNA bound/release fractions and 0.75 ml for the input 5 
fraction).  6 
PAUSE POINT, samples can be stored at -80°C for up to one week. 7 
 8 
Protease digestion TIMING ~9 h 9 
14. Thaw the eluates from Step 13 at room temperature and collect before the 10 
proteolytic treatment 50 µl from each tube for protein analysis and 10 µl for RNA 11 
analysis.  12 
15.  Treat the eluates with either LysC (option A) or ArgC (option B) proteases.  13 
A) LysC treatment 14 
i) Add 1 µl of RNase-in and 3 µg of LysC to the RNA-bound/released fraction (~300 15 
µg of eluted RNA in ~1.4 ml) and 0.5 µl of RNase-in and 1.5 µg of LysC to input 16 
samples (~150 µg of eluted RNA in ~690 µl) remaining after Step 14.  17 
Ii) Incubate for 8h at 37°C with gentle agitation (~200 rpm). 18 
B) ArgC treatment 19 
i) Add 150 µl 10x ArgC buffer to the RNA-bound/released fraction (~300 µg of 20 
eluted RNA in ~1.4 ml) and 75 µl to the input sample (~150 µg of eluted RNA 21 
in ~690 µl) remaining from Step 14 to obtain a ~1x solution. Supplement the 22 
RNA-bound/released fraction with 1 µl of RNase-in and 1 µg of ArgC and the 23 
input fraction with 0.5 µl RNase-in and 0.5 µg of ArgC. 24 
iI)  Incubate for 8h at 37°C with gentle agitation (~200 rpm).  25 
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CRITICAL STEP: (Optional) The protocol is described for the use of either LysC 1 
or ArgC, which are optimal for a large proportion of human RBPs. However, the 2 
use of other proteases may be required (see Experimental Design). In this case, 3 
adapt the digestion buffer accordingly to the manufacturer’s recommendations, 4 
avoiding the use of buffers with basic pH (higher than 8) to prevent alkaline 5 
hydrolysis of the RNA and other regents that may harm the RNA or the protein.   6 
? TROUBLESHOOTING 7 
16.  After the proteolytic treatment, collect 50 µl and 10 µl for protein and RNA 8 
analyses, respectively.  9 
PAUSE POINT, samples can be stored at -80°C up to one week. 10 
17.  Supplement the input samples (~700 µl) derived from the oligo(dT) capture in 11 
15 ml tubes with 50-10U of RNase T1 and RNase A and incubate for 1 h at 12 
37°C. After RNase treatment input samples can be processed for MS. 13 
 CRITICAL STEP: We noticed that this RNase treatment can efficiently degrade 14 
the RNA even without inactivation of the protease. This suggest that most of 15 
the protease is lost after the 8h of incubation. Thus, no inactivation step is 16 
required.  17 
? TROUBLESHOOTING 18 
 19 
Protein and RNA analyses – TIMING ~1day 20 
18.  Analyze the proteolytic treatment and RNA integrity by silver staining (following 21 
the manufacturers’ recommendations) and bioanalyzer9, respectively, using the 22 
50 µl and 10 µl fractions collected before and after the proteolytic digestion (in 23 
Steps 14 and 16, respectively).  24 
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CRITICAL STEP: Prior to the protease digestion, silver staining should reveal 1 
a complex protein pattern distributed all across the molecular sizes (Figure 2F 2 
and G). Since the protease cleaves every 17 amino acids in average, proteolytic 3 
treatment should lead to a gel lane devoid of proteins, with the exception of the 4 
protease. In contrast, RNA is expected to show the same molecular size 5 
distribution in the bioanalyzer profile in both non-treated and treated samples 6 
(Figure 2E). Only when both are satisfactory, proceed to the next step. 7 
 8 
Second oligo(dT) capture TIMING ~5h 9 
19. Use the remaining sample of RNA-bound/released fractions from Step 16 (~1.4 10 
ml; i.e. 500 µl from each of the three rounds of oligo(dT) capture minus the 11 
samples taken for quality controls in Steps 14-18) and add 10x hybridization 12 
buffer (~150 µl) to reach ~1x hybridization buffer.  13 
? TROUBLESHOOTING 14 
20. Add 500 µl of pre-equilibrated oligo(dT) magnetic beads (see Reagent Setup) 15 
to the sample and incubate for 1 h at 4°C with gentle rotation.  16 
21. Pellet the beads by placing the tube on the magnet. Wait until the beads are 17 
fully collected on the magnet. Next collect the supernatant, transfer it into a new 18 
2 ml tube and keep on ice until Step 28. 19 
22. Resuspend the bead pellet vigorously in 1 ml of ice-cold lysis buffer by pipetting 20 
up and down. Transfer the bead suspension into a 15 ml falcon tube. Fill with 4 21 
ml of lysis buffer. Incubate for 5 min at 4°C with gentle rotation. Next, collect 22 
the beads using the appropriate magnet rack and discard the supernatant.  23 
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23. Resuspend the pellet with 1 ml of ice-cold buffer 1 by vigorously pipetting up 1 
and down. Add 4 ml of buffer 1 and mix with the pipet. Collect the beads with 2 
the magnet rack and discard the supernatant. 3 
24. Resuspend the pellet with 1 ml of ice-cold buffer 2 by pipetting vigorously up 4 
and down. Add 4 ml of buffer 2 and mix with the pipet. Collect the beads with 5 
the magnet rack and discard the supernatant. 6 
25. Resuspend the pellet in 1 ml of buffer 3 (room temperature) by vigorously 7 
pipetting up and down. Add 4 ml of buffer 1 and mix with the pipet. Collect the 8 
beads with the magnet rack and discard the supernatant. 9 
26. Resuspend the bead pellet in 250 µl of elution buffer (room temperature) and 10 
transfer the bead suspension into a new low-binding, 1.5 ml tube. Incubate for 11 
5 min at 55°C with agitation in a thermomixer (~500 rpm). Move the tube to the 12 
magnet to pellet the beads and transfer the supernatant into a new low-binding, 13 
1.5 ml tube. To ensure that no residual beads remain in the eluate, put the tube 14 
in the magnet again and transfer the supernatant into a new low-binding, 1.5 15 
ml tube. Measure the RNA content (nanodrop) and keep the tube on ice.  16 
27.  Repeat Steps 21 to 26 twice using recycled beads (see Reagent Setup). 17 
Combine the eluates from the three ‘second oligo(dT) capture’ cycles and take 18 
10 µl for RNA analysis (bioanalyzer).   19 
28. Collect the supernatant (released fraction) from Step 21 and the pooled eluate 20 
(RNA-bound fraction) from Step 27 and treat them with 10U of RNase A and 21 
T1 for 30 min at 37°C. 22 
? TROUBLESHOOTING 23 
Sample preparation for MS - TIMING ~2 days 24 
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29. Adjust both the RNA-bound and released peptide solutions from Step 28 to 5 1 
mM DTT by adding the appropriate amount of 1M DTT. Incubate the samples 2 
for 30 min at 56°C. 3 
30. Add 1 M Iodoacetamide to a final concentration of 10 mM, and incubate the 4 
samples for 30 min at 20°C in the dark. 5 
31. Transfer the samples into 3 kDa centrifugal filters. Adjust the volume to 400 µl 6 
with 50 mM TEAB and concentrate the sample by centrifugation at 14,000 x g 7 
for 30 min at 4°C. 8 
CRITICAL STEP Applicable to steps 31 to 37. The samples are buffer-9 
exchanged, concentrated, and digested using Amicon Ultra centrifugal filters 10 
(0.5 ml, 3-kDa cutoff) according to the FASP protocol49 with minor modifications 11 
as indicated. Avoid primary amines in all buffers as they interfere with stable-12 
isotope dimethyl labeling. 13 
? TROUBLESHOOTING 14 
32. For buffer exchange, add 300 µl of 50 mM TEAB and centrifuge at 14,000 x g 15 
for 30 min at 4°C. Discard the flowthrough.  16 
33. Add sequencing grade trypsin at an enzyme-protein ratio of 1:50 to the 17 
samples. Since the absolute amount of protein in the samples is unknown at 18 
this point, add 0.5 µg trypsin in 50 µl 50 mM TEAB to the filter unit. Make sure 19 
the lid of the filter unit is well closed and then mix by vortexing. Insert the tube 20 
in a floating rack and incubate the filter in a wet chamber (e.g. a pipette tip box 21 
containing few ml of water; it is not necessary to seal the box) at 37°C for 14 22 
hours. 23 
? TROUBLESHOOTING  24 
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CRITICAL STEP: (optional) To ensure that the X-link peptides actually form 1 
part of the in silico generated RBDpep (LysC/ArgC fragment), an optional 2 
control omitting the treatment with trypsin can be performed (see Experimental 3 
Design).   4 
34. Place the filter on a new 2 ml tube. Collect the peptides by centrifugation at 5 
14,000 x g for 30 min at room temperature. Tryptic peptides will be present in 6 
the flowthrough (i.e. take the flowthrough).   7 
35. Wash the filter membrane by adding 50 µl of 0.5 M NaCl. Centrifuge at 14,000 8 
x g for 20 min at RT. Mix this flowthrough with that from Step 34. 9 
36. Invert the filter unit and recover the remaining sample by centrifugation at 1,000 10 
x g for 1 min at RT. Combine this eluate with the flowthrough of Step 35. 11 
37. Acidify the combined sample (eluate from Step 36) by adding formic acid to a 12 
final concentration of 1%. 13 
PAUSE POINT Samples can be frozen indefinitely at -20°C or -80°C. 14 
 15 
Stable-isotope peptide labeling and fractionation – TIMING 1 day 16 
CRITICAL: Stable isotope labeling by reductive amination in Steps 38-46 is 17 
performed according to the protocol of Boersema et al40. All labeling steps are 18 
carried out at room temperature on StageTips50. For complete labeling of 19 
primary amines, labeling solutions need to be prepared freshly on the day of 20 
usage. Avoid using larger SPE cartridges such as Sep-Pak since the 21 
concentration of peptides in the samples is low, and sample losses would be 22 
significant. 23 
38. Take two StageTips for the RNA-bound and released samples to separately 24 
label the peptides with light and heavy dimethyl labeling solutions, respectively. 25 
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If also analyzing the input samples, take two additional StageTips, one for the 1 
noCL control and one for the cCL sample. Input samples can be labeled with 2 
the same isotope pairs (light and heavy) since they will be analyzed as an 3 
independent experiment in a separate MS run. 4 
CRITICAL STEP: (optional) the medium dimethyl labeling reagent is not used 5 
here and can be used to label peptides from a paralleled non-irradiated or 6 
trypsin omitted negative control; alternatively, it can be used for a RNA-bound 7 
sample generated under different physiological conditions (see Introduction).  8 
39. To activate the StageTips load 20 µl of acetonitrile and centrifuge for 1 min at 9 
500 x g at RT. Discard the flowthrough. 10 
40. Wash the StageTips with 20 µL of buffer B, centrifuge for 1 min at 500 x g at 11 
RT and discard the flowthrough. 12 
41. Equilibrate the StageTips with 20 µL of buffer A, centrifuge for 1 min at 1,000 x 13 
g at RT. Discard the flowthrough.  14 
CRITICAL STEP Adjust the centrifugation times if the solutions have not fully 15 
passed through the StageTips. Avoid letting StageTips run completely dry 16 
during the equilibration, loading and washing steps. 17 
42. Load the whole peptide sample from the RNA-bound and released samples 18 
from Step 37 on the two activated StageTips. In other words, one StageTip will 19 
be loaded with the peptides from the RNA-bound fraction and the other with the 20 
released peptides. Load in separated StageTips the noCL and cCL input 21 
samples. Centrifuge for 2 min at 1,000 x g at RT.  22 
CRITICAL STEP: Load the sample in multiple steps if the volume exceeds the 23 
capacity of the StageTip. Increase the centrifugation time if necessary until the 24 
entire sample volume has passed through the StageTip. 25 
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43. Wash the StageTips with 20 µL of buffer A, centrifuge for 1 min at 1,000 x g at 1 
RT. Discard the flowthrough. 2 
44. Add 50 µL of the respective light, medium or heavy labeling solution for one 3 
round of labeling on the StageTips. Centrifuge at 500 x g for 10 min at RT. 4 
Discard the flowthrough. Repeat this step twice.  5 
? TROUBLESHOOTING 6 
45. Elute the labelled peptides by adding 50 µL buffer B and centrifuge 5 min at 7 
500 x g at RT. Combine the differentially labeled eluates into a new tube (i.e. 8 
combine RNA-bound and released peptides in one tube and the noCL and cCL 9 
input samples in other tube).  10 
CRITICAL STEP: (optional) Peptide fractionation by isoelectric focusing51, ion-11 
exchange52 or basic pH reversed phase chromatography53, can be performed 12 
at this point to reduce sample complexity. Fractionation increases the sample 13 
preparation time but, in general terms, will improve peptide identification in 14 
complex samples. All the fractionation methods indicated perform similarly, 15 
thus the selection of the approach should rely on the availability of equipment 16 
and expertise in the laboratory. 17 
46. Dry the sample by vacuum centrifugation.  18 
PAUSE POINT Samples can be frozen indefinitely at -20°C until mass 19 
spectrometric analysis. 20 
 21 
Peptide identification and quantification by LC-MS/MS – TIMING 1-5 days 22 
 23 
47. Reconstitute dried samples in 10µl of 5% DMSO and 1% formic acid.  24 
48. Inject an appropriate amount of sample to optimally load the LC column. Apply 25 
a linear gradient of organic solvent for peptide separation using nano-flow 26 
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HPLC. Analyze the sample using data-dependent acquisition (see 1 
Experimental Design). 2 
CRITICAL STEP: The optimal amount of peptides will depend of the efficiency 3 
of the isolation, sample preparation and MS equipment. We recommend a 4 
preliminary analysis with 10% of the sample and, based on the total peptide 5 
intensity, adjust the amount loaded to avoid overload or underload of the MS 6 
system.   7 
49. Analyze the RAW data using a software that employs peptide identification by 8 
database searching54. Filter the peptide identifications to an FDR of 1%. Extract 9 
ion chromatograms for each peptide and labeling state and determine heavy-10 
to-light ratios 11 
Data analysis – TIMING ~1 Week 12 
CRITICAL: A step by step documentation of the data analysis and the scripts used 13 
can be found in the Supplemental Methods. 14 
50. Extract ion count measures for each peptide using e.g. MaxQuant software44. 15 
51.  Analyze the peptide intensities with the software and proteome references 16 
implemented in R in packages RBDmap, RBDmapHeLa, and 17 
mRNAinteractomeHela9,29 . These packages will be used from Step 51 to 55 as 18 
indicated in the Supplemental methods. Summarize the ion count ratios 19 
between RNA-bound and released peptides for the identification of RNA-20 
binding sites, and between noCL and crosslinked input samples, using 21 
information from three biological replicates (see Supplemental Methods, 22 
sections 3-4). The RNA-bound/released peptide ratios will be used to determine 23 
the RNA-binding regions, while the cCL/noCL input peptide ratios will serve to 24 
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determine the RNA interactome and to analyze the impact of the protease of 1 
choice on the MS peptide identification (see Supplemental Methods, section 2).  2 
52. Plot the density of ratios from RNA-bound over released peptides intensities. 3 
Identify the center of the low-intensity mode (representing RNA-released 4 
peptides) with a robust estimate. Normalize the value such that the center of 5 
the mode becomes zero (see Supplemental Methods, section 5). 6 
CRITICAL STEP The distribution of ratios is expected to be bi-modal, with one 7 
mode representing the RNA bound peptides and the other mode the released 8 
ones.  9 
53. Test the normalized RNA-bound/released ion count ratios against the 10 
hypothesis that ratios are zero using three or more replicates by a moderated 11 
t-test implemented in the R/bioconductor package limma46 (see Supplemental 12 
Methods, section 6).  13 
 14 
TROUBLESHOOTING 15 
CRITICAL STEP: (optional) In our original RBDmap experiments29,30 we did not 16 
notice a large proportion of “infinite” or “zero” ratios (i.e. situation occurring 17 
when a given peptide is not detected in one of the two fractions, resulting in a 18 
zero value in the numerator or denominator that impedes the generation of a 19 
ratio). However, if the incidence of these is high in a given experiment, a 20 
semiquantitative approach that considers the reproducibility of a “zero” or 21 
“infinite” peptide intensity ratio across biological replicates can be implemented 22 
as in15,38.   23 
54. Correct p-values by the method of Benjamini-Hochberg controlling for FDR. We 24 
apply a FDR of 1% for both identification of RBPs (cCL versus noCL input 25 
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samples) and determination of RNA-binding sites (RNA-bound versus released 1 
peptides, Figure 2A) (see Supplemental Methods, section 6). 2 
55. Extend the tryptic peptide to the adjacent LysC or ArgC cleavage sites to recall 3 
the original LysC or ArgC fragments. Fragments enriched in the RNA-bound 4 
fraction with 1% FDR are classified as RBDpeps. FDR cutoff of 10% is further 5 
used to identify candidate RBD peptides (See Supplemental Methods, section 6 
7).  7 
 8 
TROUBLESHOOTING 9 
Troubleshooting advice is summarized in Table 1. 10 
 11 
TIMING 12 
Note that the time required to carry out Steps 1-16 can be reduced by scaling down 13 
the experiment or by having more than one person involved in the experiment.  14 
Step 1  Cell culture         overnight  15 
Step 2  Preparation for UV-crosslinking     ~30 min 16 
Step 3  UV-crosslinking        ~30 min 17 
Step 4  Lysis          ~15 min 18 
Step 5  Homogenization        ~30 min 19 
Steps 6-13  First oligo(dT) capture       ~ 6h 20 
Steps 14-17 Protease digestion       ~ 9h 21 
Step 18 Protein and RNA analyses     ~1 day 22 
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Steps 19-28 Second oligo(dT) capture      ~5h 1 
Steps 29-37  Sample preparation for MS     2 days 2 
Steps 38-46 Stable-isotope peptide labeling and fractionation  1 day 3 
Steps 47-49 Peptide identification and quantification by LC-MS/MS 1-5 days 4 
Steps 50-55  Data analyses       ~1 week 5 
 6 
ANTICIPATED RESULTS 7 
Analysis by mass spectrometry of the UV irradiated versus non-irradiated input 8 
samples (Figure 1) generated a protein dataset29 that closely resembles the previously 9 
described human RNA interactome (82% overlap; 1% FDR)8,9,13, implying that the 10 
LysC and ArgC treatments do not negatively affect protein identification by MS. 11 
Therefore, the experimental protocol described here also permits the determination of 12 
comprehensive RNA interactomes by analyzing the input fraction.  13 
Analysis of the RNA-bound and released fractions (Figure 1) by MS is expected to 14 
reveal thousands of peptides. Peptide intensity ratios between the RNA-bound and 15 
released fractions should follow a bimodal distribution (Figure 2A), with one mode 16 
representing the released peptides (grey dots) and the other the RNA-bound ones (red 17 
dots). A problem separating the two fractions or a peptide loss due to inefficient sample 18 
preparation is likely to yield a unimodal distribution (see Troubleshooting). RNA-19 
bound/released ratios should be consistent across the biological replicates (Figure 20 
2A)29. Identified tryptic peptides are then extended to their adjacent LysC or ArgC 21 
cleavage sites to recapitulate the protein fragments generated by these proteases 22 
during the sample digestion. Proteolytic fragments enriched in the RNA-bound fraction 23 
45 
 
with 1% and 10% FDR are referred to as RBDpeps and candidateRBDpeps, 1 
respectively. For most of the analyses we focused on the 1% FDR data sets; however, 2 
a significant fraction of bona fide RNA-binding sites can be contained in the 10% FDR 3 
dataset, which are therefore also displayed in the individual protein profiles (Figure 4A 4 
and B).   5 
Proteolytic fragments are plotted in the individual protein profiles taking their position 6 
within the protein into consideration, represented from N- to C-terminus on the x axes 7 
(Figure 4A and B). Domains are displayed as boxes below the x axis, facilitating the 8 
visual analysis of the RNA-binding sites against the domain distribution. The peptide 9 
‘fold change’ between RNA-bound and released fractions is shown on the y axis. 10 
RBDpeps (peptides enriched in the RNA-bound fraction at 1% FDR) are represented 11 
in red, candidateRBDpep (peptides enriched in the RNA-bound fraction at 10% FDR) 12 
in salmon and released peptides (peptides enriched in the released fraction at 1% 13 
FDR) in blue. In HeLa cells, the position of RBDpeps strongly correlates with classical 14 
RBDs such as RRM type 1 (p=1.7x10-79), RRM type 6 (p=1.12x10-17), CSD (p=9x10-15 
5) and Zinc fingers CCHC (1.4x10-3), showing that RBDmap efficiently identifies most 16 
of the well-established RNA-binding architectures (Figure 4A)29. Strikingly, RBDmap 17 
identified dozens of novel RBDs such as Ezrin/radixin/moesin (ERM, p=2.45x10-4), 18 
high mobility group box domain (HMGB, 6.x10-4), heat shock protein 70 domain 19 
(HSP70, p=8.9x10-3), PDZ domain (also known as Dlg homologous region, DHR, 20 
p=9x10-3) and FK506-binding protein (FKBP) domain (p=9x10-3), as well as more than 21 
six hundred RNA-binding sites mapping to intrinsically disordered regions29. These 22 
globular and intrinsically disordered RBDs are conserved across homologous and 23 
non-homologous proteins. RNA-bound fragments are more conserved across 24 
evolution than released regions, and are enriched for post-translational modifications, 25 
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suggesting biological significance29. For example, ERM proteins interact with the 1 
plasma membrane and cytoskeleton and were not previously associated with RNA 2 
biology. RBDmap identifies multiple LysC and ArgC RBDpeps overlapping at the C-3 
terminus of the ERM domain of MSN and RDX (Figure 4B and C). Interestingly, recent 4 
RBDmap datasets from our lab generated from Huh-7 cells (unpublished, RH) and 5 
mouse HL-1 cardiomyocytes30 show identical binding sites in these proteins, 6 
suggesting data consistency across biological systems and functional conservation 7 
from mouse to human (Figure 4B and C). The complete HeLa RBDmap dataset can 8 
be accessed at: http://www-huber.embl.de/users/befische/RBDmap/.   9 
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FIGURE LEGENDS 2 
Figure 1: Schematic representation of RBDmap. RBP, RNA-binding protein. 3 
RBDpep refers to the RNA-bound peptide generated by LysC or ArgC proteolysis. 4 
RBDpeps are hydrolyzed by trypsin treatment into two type of peptides: the RNA-5 
crosslinked peptide (X-link) and its neighboring tryptic peptides (N-link). N-link 6 
peptides exhibit normal mass and are used to identify the RBDpeps. Adapted with 7 
permission from29.   8 
Figure 2: RBDmap quality controls and data analysis. A) Scatter plot comparing 9 
the peptide intensity ratios between RNA-bound and released fractions from two 10 
independent experiments (i.e. replicates). 1%FDR RBDpeps and 10% FDR candidate 11 
RBDpeps are shown in red and salmon, respectively. (r: Pearson correlation 12 
coefficient). The scatter shows an excellent correlation between biological replicates 13 
(r= 0.85) and that the identified peptides follow a bimodal distribution. One mode 14 
represents the RNA-bound peptides (N-link) in red, and the other the released 15 
peptides (grey).  B) In silico prediction of protease suitability for RBDmap (see section 16 
Anticipated results). The bar plot represents the number of proteins for which protease 17 
cleavage would lead to the identification of an RNA-binding site smaller than the 20% 18 
of the protein length (i.e. high resolution RBD identification). C) HeLa cells were 19 
incubated either in the presence or the absence of 4SU. Non 4SU-treated cells were 20 
UV254 irradiated (cCL) or mock-irradiated (noCL), while 4SU-labeled cells were UV365 21 
irradiated (PAR-CL) or non-irradiated (4SU noCL). After oligo(dT) capture, proteins 22 
were analyzed by silver staining. A complex protein pattern (composed by RBPs) is 23 
observed only when cells are irradiated with UV light. In absence of irradiation, the 24 
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resulting lane is devoid of proteins. D) Optimization of LysC treatment. After UV 1 
treatment and oligo(dT) pulldown, eluates were treated with increasing amounts of 2 
LysC for 8h at 37°C or for 16h at 22°C. Protein integrity is analyzed by SDS-PAGE on 3 
a 15% acrylamide gel, followed by silver staining.  The complex pattern of RBPs 4 
gradually disappears after treatment with increasing amounts of LysC. Complete 5 
protein cleavage (except for LysC itself, which is indicated with an asterisk (*)) is 6 
achieved with 1µg of LysC. E) RNA integrity from eluates in panel D was assessed 7 
using a bioanalyzer (RNA pico chip). After protease treatment, all samples show the 8 
same RNA pattern than the eluate from Step 13 (i.e. prior to the addition of the 9 
protease). However, incubation for 8 h at 37°C in absence of protease leads to a 10 
substantial increase in RNA products of low molecular size (lane 2), suggesting RNA 11 
degradation. F and G) Protein integrity quality controls of an RBDmap experiment in 12 
HeLa (F) and Huh-7 (G) cells. After UV crosslinking and oligo(dT) capture (cCL lanes), 13 
RBPs were eluted and treated with 3µg of LysC for 8h at 37°C. Samples taken before 14 
(0h LysC) and after (8h LysC) the protease treatment were analyzed by silver staining. 15 
Almost no protein is detected in the non-irradiated (noCL) control irrespective of the 16 
protease treatment. Conversely, a complex protein pattern is observed in the UV 17 
irradiated samples, which disappears after 8h of protease treatment at 37°C. The LysC 18 
and RNase T1 lanes show the mobility of these proteins, indicated by an asterisk, in 19 
a SDS-PAGE gel.  Panels B, D and E are reprinted with permission from29.   20 
Figure 3. From cell culture to lysis. Workflow of the treatments performed from cell 21 
seeding until lysis, indicating the number of dishes used for each control and 22 
experimental sample. 4SU, 4-thiouridine; noCL, non-irradiated; cCL, conventional 23 
crosslinking (254 nm UV light); PAR-CL, photoactivatable ribonucleoside–enhanced 24 
crosslinking (i.e. 4SU mediated crosslinking at 365 nm UV light).  25 
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Figure 4. Analysis of individual RBDmap protein profiles. A) The RRM-containing 1 
proteins NCL and eIF3G are shown applying the single protein profile display. The X 2 
axis represents the protein length from N- to C-terminus, while the Y axis shows the 3 
fold change between RNA-bound and released fractions for each individual peptide. 4 
LysC and ArgC fragments are shown in red (1%FDR RBDpeps), salmon (10%FDR 5 
candidateRBDpeps) or blue (released fragments) lines. B) Individual map of the MSN 6 
protein from HeLa and Huh-7 RBDmap data. The protein profile is displayed as in (A). 7 
C) Homology model of the ERM domain of MSN using phyre255. RBDpeps from HeLa 8 
(left) and Huh-7 (right) cells are displayed in red.    9 
 10 
Supplementary Methods. RBDmap data analysis pipeline. A detailed example 11 
analysis workflow for RBDmap data based on R packages described in9,29,30.  12 
Table 1. Troubleshooting advice. 13 
 14 
Step Problem Possible reason Solution 
49 Low peptide yield 
after MS 
Low number of cells Calibrate the number of cells by 
performing an experiment with a fixed 
amount of beads and lysis volume but 
increasing amount of cells. We noticed 
that more cells are required when their 
volume is small (e.g. mouse embryonic 
stem cells) or when they express 









Some cell lines may require optimization 
(e.g. fragile and suspension cells or cells 
with small cytoplasms). We recommend 
testing different processing approaches 
and energies of UV irradiation if the 
crosslinking is inefficient compared to the 
same amount of total starting material in 




5 Viscous lysate Chromatin 
precipitation 
Initially, repeat the homogenization 
cycles until the viscosity is notably 
reduced. Increase the force by which the 
sample is passed through the needle. 
Use alternative homogenization methods 
such as French press or tissue 
homogenization systems.  
18 Inefficient digestion Protease activity or 
sample complexity 
Adjust the protease concentration to the 
samples using small scale pilot 
conditions. The protease activity is 
maximal at 8-8.5 pH, however, we do not 
recomment increasing the pH over 7.8 
since RNA degradation may occur at 
higher pH.   
18 RNA degradation RNases in the 
eluate 
We recommend increasing the 
concentration of RNasin or supplement 
the buffer with ribonucleoside vanadyl 
complex (NEB, S1402S) 
49 Low peptide yield 
after MS 
Peptides are lost 
during FASP 
RNase treatment can be done after the 
trypsin treatment. RNA helps to retain the 
peptides in the filter unit.   
49 MS Signal is 
dominated by tryptic, 
LysC or ArgC 
autolysis fragments 




Decrease the amount of the problematic 
protease. Small scale optimisation 
experiments will help to define the 
minimum concentration of protease able 
to proteolyze efficiently with neglegible 
miscleavages.  





Increase the volume of 1x of hybridization 
buffer to 10 ml and the amount of beads 
to 2 ml.  
49 Low peptide yield 
after MS 
Peptides are lost 
during FASP 
FASP can be replaced by in solution 
digestion.  





StageTips too fast 
Adjust the centrifugation speed and 
duration in order to decrease the flowrate 
of the labeling solutions through the 
StageTips. 
51 High incidence of 
infinite and zero 
ratios 
Indentification of low 
abundant peptides.   
Apply a semiquantitative method to 
determine whether these hits are true or 
false positives. See reference 15. 
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Figure 4 (Castello et al)
